Background: Non-AIDS-defining cancers increasingly contribute to mortality among human
Of studies comparing cancer prognosis by HIV status, HIV infection has been associated with increased mortality from multiple NADCs, including HL (13) (14) (15) and lung, (13, 14, 16, 17) colorectal, (13, 14) anal, (14, 18) and prostate (14) cancers. However, while mortality from AIDS and other causes may result in reduced survival for HIV-infected individuals, few studies have examined cancer-specific mortality (16) ; furthermore, several were conducted among individuals living with AIDS, (13, 14) who are at particularly high risk of death from non-cancer causes. Despite differences by HIV status in mortality risk factors, such as smoking (19, 20) and cancer treatment (21, 22) , few studies have had available data or adequate sample size to adjust for these factors in analyses of individual cancers. (16, 17) Finally, cancers may be diagnosed at a more advanced stage or earlier age among HIV-infected individuals; (23, 24) (16, 17) In this study, we evaluated the association of HIV infection with age and cancer stage at diagnosis and initial cancer treatment among HIV-infected and HIV-uninfected individuals diagnosed with NADCs within the same healthcare system, focusing on cancers that are commonly observed among HIV-infected individuals. We then assessed the role of HIV infection in cancer-related mortality after adjustment for age and cancer stage at diagnosis, cancer treatment, smoking, and other mortality risk factors.
MATERIALS AND METHODS

Study Design, Setting, and Population
The study population of HIV-infected and HIV-uninfected subjects with cancer diagnoses was ascertained from a previously described cohort.(25) Briefly, the source cohort consisted of 24,768 HIV-infected and 257,600 demographically matched HIV-uninfected individuals within Kaiser Permanente (KP) Northern and Southern California (KPNC and KPSC, respectively), identified and followed from 1996 through 2011. HIV-infected subjects were identified using HIV registries including all known cases of HIV/AIDS since the early 1980s for KPNC and 2000 for KPSC, with HIV-infected status confirmed by review of medical charts or medical center case lists. Individuals not included in the registries were considered HIV-uninfected. HIV-uninfected subjects were frequency-matched 10:1 to HIV-infected subjects on year and age at start of follow-up (five-year age groups), sex, and medical center. For the present study, subjects with incident diagnoses of HL or anal, prostate, colorectal, or lung cancers were selected from the source cohort. We focused on these cancers because they are the most commonly diagnosed NADCs among HIV-infected KP members; (25) there were insufficient cases to analyze cancers that are less prevalent in this population, such as melanoma, oral cancer, or liver cancer. For each cancer of interest, individuals were selected at the time of their first cancer diagnosis during the study period. Individuals with any of the five cancer diagnoses in the two years prior to study entry were considered prevalent cases and excluded. Analyses of age, stage at diagnosis, and treatment included all cases diagnosed during 1996-2011. For survival analyses, subjects were followed from cancer diagnosis until the earliest of cancer-related death, death from other causes, five years past the cancer diagnosis, or December 31, 2010 (the latest date for which data were available on cause of death).
The institutional review boards at KPNC and KPSC approved this study with a waiver of written informed consent.
Data Sources
Cancer registries. Cancer diagnoses were ascertained from the KP cancer registries, certificate data, our outcome included deaths from any cancer to account for the potential misclassification of deaths attributed to another cancer site (e.g., death from metastatic disease). This method has been used previously to account for the underestimation of mortality that may occur when only site-specific cancer deaths are analyzed. (27) Other data extracted from the EMR included age; race/ethnicity; health plan enrollment periods; and clinical diagnoses of smoking/tobacco use (ICD-9: 305.1, V15, V65, 649, internal social history codes).
Subjects without a smoking diagnosis were considered non-smokers.
Statistical Analysis
Variables considered in the analysis included age (<40, 40- Surgery is rarely used for treatment of HL and chemotherapy is not a standard treatment for prostate cancer; thus, those treatments were not assessed for those cancer types. We compared five-year survival by HIV status using Kaplan-Meier curves and log-rank tests.
Subjects were censored if they died from non-cancer-related causes; thus, the survival curves are interpreted as the theoretical probability of dying from cancer-related causes if no subjects died of non-cancer-related causes. Hazard ratios (HR) for cancer-related mortality were obtained from Cox regression models comparing HIV-infected to HIV-uninfected subjects.
Demographics-adjusted models included variables for age, race/ethnicity, and sex, while fully adjusted models additionally included TNM stage, cancer treatment type, and smoking.
Analyses were conducted in SAS 9.1 (Cary, NC). Statistical tests were two-sided and statistical significance was defined as P<0.05.
RESULTS
Study Population
Among HIV-infected and HIV-uninfected subjects, there were 120 and 28 cases of anal cancer, and 68 and 51 of HL, respectively. Subjects were mostly men overall, with a higher proportion of men among HIV-infected compared with HIV-uninfected subjects with anal cancer (P<0.001), and a lower proportion among HIV-infected subjects with colorectal cancer (P=0.032; Table 1 ). The distribution of race/ethnicity differed by HIV status for prostate cancer (P=0.003) and lung cancer (P=0.006), with a higher proportion of white subjects among HIVinfected compared with HIV-uninfected individuals. Among HIV-infected subjects, MSM was the most common HIV-transmission risk factor for all cancers, reflecting the epidemic in California.
Age and Stage at Diagnosis by HIV Status
Compared with HIV-uninfected subjects, HIV-infected subjects were younger when diagnosed with anal (52 vs. 56 years, P=0.019), colorectal (53 vs. 58 years, P=0.002), and lung cancers (56 vs. 61 years, P<0.001), while age was similar by HIV status for prostate cancer and HL (Table 1) . TNM and SEER summary stage were similar by HIV status for anal, colorectal, and lung cancers (Table 2) . However, compared with HIV-uninfected subjects, HIV-infected subjects with HL were more frequently diagnosed with Stage IV disease (54% vs. 28%, P=0.007). For prostate cancer, HIV-infected subjects were more frequently diagnosed with localized disease (89% vs. 83%, P=0.023), but there were no differences in TNM stage by HIV status.
Cancer Treatment by HIV Status
The proportion receiving any cancer treatment within six months of diagnosis was lower for HIV-infected compared with HIV-uninfected subjects with lung cancer (64% vs. 76%, P=0.023), but similar by HIV status for all other cancers (Table 2 ). There were no differences in cancer treatment type by HIV status for anal cancer. However, for prostate cancer, HIV-infected subjects more frequently received radiation compared with HIV-uninfected subjects (31% vs. 
Cancer Mortality by HIV Status
The number of deaths from cancer-related and other causes is shown in Table 2 . 
DISCUSSION
In this large cohort study, HIV-infected individuals were diagnosed at an earlier age for anal, colorectal, and lung cancers, and a more advanced stage for HL, compared with HIVuninfected individuals from the same healthcare system. Five-year survival was lower for HIVinfected compared with HIV-uninfected individuals for all NADCs examined, reaching statistical significance for lung cancer. After adjustment for age, race/ethnicity, sex, stage, cancer treatment, and smoking, HIV-infected individuals were at significantly higher risk of cancerrelated mortality after diagnosis with lung cancer or prostate cancer, but not HL, anal cancer, or colorectal cancer.
Our study is consistent with prior studies finding reduced survival among HIV-infected individuals diagnosed with lung and prostate cancers, (13, 14, 16, 17) While several studies have identified an earlier age at NADC diagnosis for HIV-infected individuals compared with the general population,(36-39) few have accounted for differences in the underlying age distributions of these two populations. Shiels et al. adjusted for age in a registry-based study,(39) while our study matched HIV-uninfected to HIV-infected subjects on age. Similar to our study, Shiels et al. found that individuals with AIDS were younger when diagnosed with anal and lung cancers compared with the general population; these comparable results are reassuring, given that our studies used different analytical approaches to remove the potential age bias. In addition to HIV-associated mechanisms that increase incidence and progression of NADCs, earlier age at diagnosis among HIV-infected individuals may be attributable to increased medical surveillance. In this study population, we previously found (40) However, we found no differences in stage by HIV status for cancers detected at a younger age among HIV-infected individuals, suggesting that earlier diagnosis may be attributable to a biological effect rather than differences in screening.
We observed less treatment for HIV-infected individuals with lung cancer, as well as There are several limitations of our study. First, despite our large cohort, our statistical power was limited. We observed relatively small numbers of HL diagnoses overall and anal 
cancer diagnoses among HIV-uninfected subjects, which may explain the lack of statistical significance observed for these cancers. Few observed deaths for most cancers may also have limited our ability to detect differences in cancer mortality. Second, because treatment data from the EMR were not comprehensive for all cancer cases and medical centers, we relied on the cancer registries for cancer treatment data. These data may be subject to misclassification and only document treatments initiated within six months after diagnosis. Third, an analysis of cancer recurrence may have strengthened our findings, but these data were not available.
Fourth, because data were extracted from the EMR, risk factors such as smoking could not be analyzed in detail. Fifth, diagnosis and surgery may have been more likely to be misclassified for anal cancer than for other cancers because of the high prevalence of precancerous or in situ disease and the use of local treatment for microinvasive disease. Sixth, our survival analysis represented the theoretical scenario in which subjects only died of cancer-related causes; future studies with larger sample sizes should consider approaches accounting for competing risks. However, in this analysis, most deaths were cancer-related. Finally, our subjects were mostly men, limiting the generalizability of our results to women.
Our study also has several strengths. First, cancers were identified from HIV-infected individuals and an internal comparison group of HIV-uninfected individuals from the same healthcare system, in which differences in outcomes were unlikely to be attributable to differential access to care. Second, matching HIV-uninfected to HIV-infected individuals on age allowed us to compare age at diagnosis despite differences in the underlying age distributions of these populations. Third, including data on TNM stage, a more clinically relevant measure of cancer stage than SEER summary stage, we were able to determine that reduced survival for 
